Trevi Therapeutics, Inc. (TRVI) - Form 8-K Summary
Business Context and Reporting Period
Trevi Therapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on March 18, 2025. The filing serves to announce the Company's financial results for the quarter and full year ended December 31, 2024. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the press release (Exhibit 99.1) but are not detailed within the body of this Form 8-K document.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the incorporated press release for comparative financial analysis.
Guidance, Outlook, and Risks
The filing text does not include specific guidance, outlook, management commentary, or risk factors. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference except as expressly set forth.
Key Facts for Investor Verification
- Verify the specific financial results for the quarter and year ended December 31, 2024, by reviewing Exhibit 99.1 (Press Release) attached to this filing.
- Confirm the Company's cash position and runway, as these figures are not present in the 8-K summary text.
- Note that the financial data in this filing is furnished, not filed, which may impact liability and incorporation into other SEC documents.
- Check the Nasdaq Stock Market listing status for Common Stock (TRVI) as referenced in the filing.